Buy & Sell Apellis Pharmaceuticals Inc (APLS) – Apellis Pharmaceuticals Inc Price Today
Aura AI Summary
Key Stats
- $5.25BMarket Cap
- HealthSector
- -25.57%3M Drawdown
- $5.32BEnterprise Value
- -Dividend Yield
- 4 daysTypical Hold Time
Apellis Pharmaceuticals Inc (APLS) is currently valued at a market capitalization of $5.25B, with an enterprise value of $5.32B. Over the past 52 weeks, Apellis Pharmaceuticals Inc has traded between a low of $16.36 and a high of $41.12, highlighting its annual price range. Over the past three months, Apellis Pharmaceuticals Inc has recorded a drawdown of -25.57%, reflecting recent price volatility. On average, investors hold Apellis Pharmaceuticals Inc for approximately 4 days, indicating typical investor behavior on the platform.
About Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals is a biopharmaceutical company focused on complement science. It develops therapies for serious diseases, including the first-ever treatment for geographic atrophy, a leading cause of blindness.
Most Recent News
Reaves Utility Income Fund targets rising electricity demand with 12% upside and 5% yield potential
The Reaves Utility Income Fund is an aggressive, actively managed fund focused on companies benefiting from increasing electricity demand, particularly driven by data center growth. The fund's portfolio aligns with top sector picks and shows potentia...
Mobia Medical shares fall 20% on IPO debut amid rising losses despite strong sales growth.
Mobia Medical went public but saw its shares drop over 20% on the first day, reflecting investor caution. The company’s Vivistim Paired VNS system targets the stroke recovery market, with revenues expected to double to $32 million by 2025. However, o...
S&P 500 hits record high near 7,400, extending six-week winning streak.
The S&P 500 reached a new record high, approaching the 7,400 level, marking its sixth consecutive week of gains. This streak matches the longest winning run since October, with the index rising 2.3% in the past week and 8.08% year-to-date. The consis...